EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative Effectiveness of Infliximab vs Ustekinumab for Endoscopic and Transmural Remission in Biologic Naïve Crohn’s Disease

Zicheng Huang, Na Diao, Qin Guo, Miao Li, Wenjie Cheng, Qingfan Yang, Hongsheng Yang, Zhaopeng Huang, Lishuo Shi, Jian Tang, Xiang Gao, Kang Chao

Clinical Gastroenterology and Hepatology · 2026-01 · 24 (1) · 172-180

DOI: 10.1016/j.cgh.2024.12.040 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-01. Verfasst von Zicheng Huang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, P. R. China; Guangdong Provincial Key Laboratory of…. Hauptthemen laut MEDLINE: Ustekinumab, Crohn Disease, Infliximab, Gastrointestinal Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: National Key Clinical Specialty Discipline Construction Program of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Active-comparator studies are important to clinical decision-making. We compared the effectiveness of infliximab vs ustekinumab for endoscopic and transmural remission in biologic-naïve Crohn's disease (CD). METHODS: This was a prospective real-world cohort study that included biologic-naïve patients with CD initiating infliximab or ustekinumab therapy. We compared endoscopic remission, endoscopic response, transmural remission, transmural response, clinical remission, and C-reactive protein (CRP) remission at weeks 14 to 26 and 44 to 56, using multiple logistic regression and propensity score matching to adjust for confounders. RESULTS: In total, 429 patients were included (283 infliximab and 146 ustekinumab). At weeks 14 to 26 and 44 to 56, no significant differences were found between infliximab and ustekinumab groups in the rates of endoscopic remission (37.5% vs 30.8%; adjusted odds ratio [aOR], 1.42; 95% confidence interval [CI], 0.89-2.25; 37.5% vs 35.6%; aOR, 1.10; 95% CI, 0.71-1.72), endoscopic response (60.8% vs 55.5%; aOR, 1.27; 95% CI, 0.83-1.95; 52.7% vs 49.3%; aOR, 1.14; 95% CI, 0.75-1.76), transmural remission (16.7% vs 14.7%; aOR, 1.23; 95% CI, 0.64-2.38; 30.0% vs 28.7%; aOR, 1.10; 95% CI, 0.65-1.87), transmural response (40.1% vs 34.1%; aOR, 1.23; 95% CI, 0.76-2.00; 47.6% vs 42.6%; aOR, 1.19; 95% CI, 0.75-1.90), and clinical remission (73.2% vs 62.3%; aOR, 1.54; 95% CI, 0.96-2.48; 73.5% vs 71.2%; aOR, 1.14; 95% CI, 0.71-1.85). The infliximab group had a higher CRP remission rate at weeks 14 to 26 (60.1% vs 61.6%; aOR, 1.85; 95% CI, 1.17-2.93), but rates were similar at weeks 44 to 56 (72.8% vs 71.4%; aOR, 0.99; 95% CI, 0.65-1.52). By week 56, treatment discontinuation rates were also comparable between the infliximab and ustekinumab groups (24.4% vs 20.5%; P = .372). Similar results were replicated in the propensity-matched cohort. CONCLUSIONS: Infliximab and ustekinumab demonstrated similar effectiveness in achieving clinical, endoscopic, and transmural remission in biologic-naïve patients with CD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UstekinumabCrohn DiseaseInfliximabGastrointestinal AgentsHumansMaleFemaleAdultProspective StudiesRemission InductionTreatment OutcomeMiddle AgedYoung Adult

Stichwörter der Autor:innen

Crohn’s DiseaseEndoscopic RemissionInfliximabTransmural RemissionUstekinumab

Substanzen

UstekinumabInfliximabGastrointestinal Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, P. R. China; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, the Sixth Affiliated Hospital,…
  • Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, P. R. China; Biomedical Innovation Center, the Sixth Affiliated Hospital, Su…
  • Center of Clinical Research, the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, PR China.

Förderung

  • National Key Clinical Specialty Discipline Construction Program of China
  • National Key Research and Development Program of China

Zitieren

APA

Huang, Z., Diao, N., Guo, Q., Li, M., Cheng, W., Yang, Q., Yang, H., Huang, Z., Shi, L., Tang, J., Gao, X., & Chao, K. (2026). Comparative Effectiveness of Infliximab vs Ustekinumab for Endoscopic and Transmural Remission in Biologic Naïve Crohn’s Disease. Clinical Gastroenterology and Hepatology, 24(1), 172-180. https://doi.org/10.1016/j.cgh.2024.12.040

Vancouver

Huang Z, Diao N, Guo Q, Li M, Cheng W, Yang Q, et al. Comparative Effectiveness of Infliximab vs Ustekinumab for Endoscopic and Transmural Remission in Biologic Naïve Crohn’s Disease. Clinical Gastroenterology and Hepatology. 2026;24(1):172-180. doi:10.1016/j.cgh.2024.12.040

BibTeX
@article{Huang2026,
  author = {Huang, Zicheng and Diao, Na and Guo, Qin and Li, Miao and Cheng, Wenjie and Yang, Qingfan and Yang, Hongsheng and Huang, Zhaopeng and Shi, Lishuo and Tang, Jian and Gao, Xiang and Chao, Kang},
  title = {Comparative Effectiveness of Infliximab vs Ustekinumab for Endoscopic and Transmural Remission in Biologic Naïve Crohn’s Disease},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {1},
  pages = {172--180},
  doi = {10.1016/j.cgh.2024.12.040}
}
Kostenlos starten →